Daniel C. Montano, Chairman, President and CEO of CardioVascular BioTherapeutics

Interactive Q&A: Daniel Montano, Chairman, President and CEO of CardioVascular BioTherapeutics Inc. (CVBT.OB)

Dr. Stegmann and our medical management team have felt for years that the best way to delivery our drug is via the least invasive method for the patient. We have debated and pondered this for many years. After our successful Phase I, clinical heart trial was completed, our team started to prepare the Phase II. With their desire for catheter delivery and guidance from other scientists, it was decided now was the time to make this change. With the support and guidance of the Cordis Company ( a Johnson and Johnson company), we were able to develop a Protocol which the USA FDA has now allowed. So we are very happy. We believe this change allows us to recruit patents quicker, lower the cost of the treatment, make the treatment easier for the patents, doctors and provides for a control group in this trial. We also believe that if the drug is approved the best method to deliver the drug is via a catheter and so we made this move also in anticipation of the commercialization of our drug and the therapy.